Key Takeaways AstraZeneca gained EU approval for Imfinzi to treat muscle-invasive bladder cancer in adults. Imfinzi showed a 32% reduced risk of disease progression or death in the NIAGARA phase III study. Imfinzi sales rose 16% in Q1 2025 to $1.26B, driven by lung and liver cancer treatment demand.AstraZeneca (AZN) announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a bladder cancer indication in the European Union (EU).The regulatory body in Europe ...